Taysha Gene Therapies Inc
NASDAQ:TSHA

Watchlist Manager
Taysha Gene Therapies Inc Logo
Taysha Gene Therapies Inc
NASDAQ:TSHA
Watchlist
Price: 1.72 USD Market Closed
Market Cap: 352.6m USD

Operating Margin
Taysha Gene Therapies Inc

-1 039.5%
Current
-935%
Average
-6.6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 039.5%
=
Operating Profit
-86.6m
/
Revenue
8.3m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Taysha Gene Therapies Inc
NASDAQ:TSHA
352.5m USD
-1 039%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
373.8B USD
29%
US
Amgen Inc
NASDAQ:AMGN
168.4B USD
22%
US
Gilead Sciences Inc
NASDAQ:GILD
138.9B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.7B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
121.1B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73.1B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
32.9B EUR
-1%

Taysha Gene Therapies Inc
Glance View

Market Cap
352.5m USD
Industry
Biotechnology

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas and currently employs 178 full-time employees. The company went IPO on 2020-09-24. The firm is focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). Its portfolio of gene therapy candidates targets a range of neurological indications across three distinct therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders and genetic epilepsies. Its product candidates include TSHA-101, which is being developed for the treatment of giant axonal neuropathy (GAN); TSHA-102, a neurodevelopmental disorder product candidate, which is being developed for the treatment of Rett syndrome; TSHA-118, which is a AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter, and TSHA-105, a gene replacement therapy for the treatment of SLC13A5 deficiency.

TSHA Intrinsic Value
2.85 USD
Undervaluation 40%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 039.5%
=
Operating Profit
-86.6m
/
Revenue
8.3m
What is the Operating Margin of Taysha Gene Therapies Inc?

Based on Taysha Gene Therapies Inc's most recent financial statements, the company has Operating Margin of -1 039.5%.

Back to Top